CFGS
NKTR icon

Concourse Financial Group Securities’s Nektar Therapeutics NKTR Stock Holding History

Concourse Financial Group Securities’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3
Closed -$928 – 2263
2019
Q4 		$1K Buy
+3
New +$870 ﹤0.01% 1994

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Concourse Financial Group Securities's NKTR Position: Q1 2020 in Review

Concourse Financial Group Securities sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 3 shares — an estimated $928 sold.

Concourse Financial Group Securities first reported a position in NKTR in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 244 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

  • Concourse Financial Group Securities reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Concourse Financial Group Securities sold 3 Nektar Therapeutics shares in Q1 2020, an estimated $928.
  • Concourse Financial Group Securities first reported a position in Nektar Therapeutics in Q4 2019 and held it in 1 quarter.
  • Concourse Financial Group Securities's Nektar Therapeutics position peaked at $1K in Q4 2019.
  • 244 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Concourse Financial Group Securities's 13F filing for Q1 2020, filed 13 May 2020.